Human interferon entered the supplementary list of the drug catalogue of new coronavirus infected people in Yunnan Province (trial first version).

The efficacy of interferon α1b (Serokin) in broad-spectrum antiviral has been continuously favored by the market, and with the optimization and adjustment of epidemic prevention and control policies, the whole country has entered a new stage of epidemic prevention and control, superimposed on the high incidence season of autumn and winter influenza, the shipment and order volume of Sinovac pharmaceutical products Cerokin have increased
significantly.
The company's production line is running at full capacity, working overtime to catch up with production and ensure supply
.

Just on December 29, the Yunnan Provincial Health Commission released the "Yunnan Province New Coronavirus Infection Drug Catalogue (Trial First Edition)" supplemented the list of
drugs.
14 proprietary Chinese medicines, 37 hospital traditional Chinese medicine preparations and 1 western medicine were added for fever, cough and other symptoms, and 8 types of western drugs were added for antiviral and immunotherapy purposes, among which, recombinant human interferon (limited to pediatrics) entered the
supplementary list of drugs for new coronavirus infected patients in Yunnan Province (trial first version).

Interferon is a class of proteins with broad-spectrum antiviral, antitumor and immunomodulatory effects, and is a key component of
the body's innate immunity.
At present, three subtypes of human interferon α have been approved for clinical use as drugs, namely -α1b, -α2a and -α2b, all of which are genetically engineered products
.
Among them, human interferon α1b was first obtained by the famous Chinese virologist - Academician Hou Yunde from healthy Chinese white blood cells, and was industrially produced and marketed
in Shenzhen Kexing in 1996.

In recent years, human interferon α1b has made significant research progress and excellent clinical efficacy
in the treatment of a variety of viral infections and tumor diseases.
In previous large-scale infectious virus incidents, such as the fight against SARS in 2003 and the Middle East respiratory syndrome in 2015, interferon α has played an important role
.
In the early days of the fight against the epidemic in early 2020, Sinovac responded to the call as soon as possible and rushed more than 5 million injectable human interferon α1b (Serokin) to the national anti-epidemic frontline to provide drug support
for epidemic prevention and control.

This year, Sinovac Pharmaceutical interferon has made important progress in innovative research and development, α1b inhalation solution obtained clinical approval, the indication is mainly for pediatric respiratory syncytial virus lower respiratory tract infection (pneumonia, bronchiolitis), is a special drug for children, through aerosolized inhalation administration, the active ingredient can directly reach the lesion, faster onset, higher acceptance and safety of pediatric patients
.

In recent years, the sales of the company's core product "Seruojin" have maintained a steady growth trend, according to the data results of Minai.
com, "Seruojin" ranked first in the domestic short-acting injectable human interferon market share in 2021, with a market share of 30.
33%.